Fig. In situ transplantation tumour model based on HepG2-Luc hepatocellular carcinoma cells (host mouse: M-NSG). a. Model tumourigenic curve versus body weight curve; b. Photograph of mouse liver; c. Mouse live imaging image.

Fig. Lung in situ graft tumour model constructed based on the human SHP-77-Luc lung cancer cell line.

Fig. Pancreatic in situ graft tumour model constructed based on the human PANC-1-Luc pancreatic cancer cell line.

Fig. Cervical transplantation in situ tumour model constructed based on the human Hela-Luc cervical cancer cell line.

Fig. In situ graft tumour model of glioma constructed based on the human U87MG glioma cell line.

Fig. In situ transplant tumour model of bladder cancer constructed based on the human RT112-Luc bladder cancer cell line.

Fig. Femoral injection bone metastasis model constructed based on the human MDA-MB-231-Luc breast cancer cell line.

Fig. Anti-tumour drug efficacy validation experiments using the CDX model of ovarian cancer cell line (SK-OV-3).

Fig. CAR-T cell therapy efficacy validation experiment using lung cancer cell line (A549) CDX model.

Fig. mRNA anti-tumor drug efficacy validation experiments using the CDX model of the B-lymphoblastic leukaemia cell line (Nalm6-Luc).